10x Genomics, Inc.

10x Genomics, Inc.

TXGNYSE / NASDAQHealthcareSmall cap

$51.80-$5.58 (-9.7%)

Last close · Data as of Nov 20, 2026

Market cap
$4.3B
P/E
-97.7x
EV / EBITDA
988.3x
Revenue
$642.8M
Net margin
-6.8%
ROCE
-12.5%

+214.7% over the last year

10x Genomics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-27.5%
3M
-18.9%
6M
+116.0%
1Y
+214.7%
5Y
-65.5%

52-week range

Day change -$5.58 (-9.7%) from $57 to $52 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TXG, bought on each weekday since 2021.

News & filings

What 10x Genomics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 43.5 million US dollars in fiscal 2025.

Strengths (1)

  • Free cash flow was 20.2% of revenue in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.

Read moreShow less

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Sector
Healthcare
Shares outstanding
127.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$4.3B
P/E
-97.7x
P/B
5.3x
EV / EBITDA
988.3x
EV / Sales
6.0x
P/S
6.6x
52-week high
$97.74
52-week low
$15.46

Profitability

Operating margin
-17.2%
Net margin
-6.8%
EBITDA margin
0.6%
ROE
-5.5%
ROCE
-12.5%
ROIC
-7.8%
ROA
-4.2%
Asset turnover
0.62

Growth

Revenue
$642.8M
Revenue growth, 1Y
5.2%
Revenue CAGR, 3Y
7.6%
Net profit growth, 1Y
-76.2%
Free cash flow
$130.1M

Solvency

Current ratio
4.46
Debt / Equity
0.11
Debt / Assets
0.08
CFO / Net profit
-3.12
Cash / Market cap
11.1%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$642.8M
Cost of revenue$198.9M
Gross profit$443.9M
Operating expenses$554.8M
Research and development$238.6M
Selling, general and administrative$316.1M
Operating income-$110.9M
Interest and other$71.0M
Pretax income-$39.9M
Tax and other$3.6M
Net income-$43.5M

Revenue and net profit

Revenue grew 5.2% in FY2025; net profit is the dashed line.

10x Genomics, Inc. revenue and net profit by fiscal year
10x Genomics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$516.4M-$166.0M
FY2023$618.7M-$255.1M
FY2024$610.8M-$182.6M
FY2025$642.8M-$43.5M

Cash flows

FY2025: $136.1M from operations, $130.1M free after investment (dashed).

10x Genomics, Inc. operating and free cash flow by fiscal year
10x Genomics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$33.6M-$165.3M
FY2023-$15.2M-$64.7M
FY2024$6.7M-$6.7M
FY2025$136.1M$130.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$642.8M+5.2%1Y
EBITDA
$3.9M
Net profit
-$43.5M
Cash from operations
$136.1M+1,941.6%1Y
Free cash flow
$130.1M
Revenue CAGR, 3Y
7.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$642.8M$3.9M-$43.5M$130.1M-5.5%+5.2%-76.2%

Monthly returns

Month-by-month returns of TXG across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.0B
Liabilities$245.0M
Equity$796.3M
Paid-in capital$2.3B
Retained earnings-$1.5B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TXG highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. 10x Genomics, Inc. (this company)6.0x

Not shown (no positive earnings and no EV / Sales): Celcuity Inc., Erasca, Inc., Edgewise Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
10x Genomics, Inc.TXGthis company$4.3B-97.7x5.3x-5.5%988.3x
Twist Bioscience CorporationTWST$4.6B-59.3x9.7x-16.4%-40.4x
Dianthus Therapeutics, Inc.DNTH$4.6B-28.3x9.3x-32.9%-25.6x
Amicus Therapeutics, Inc.FOLD$4.5B-167.8x16.6x-9.9%88.8x
Celcuity Inc.CELC$4.5B-25.5x44.8x-176.1%-29.2x
Travere Therapeutics, Inc.TVTX$4.3B-168.1x37.4x-22.2%203.9x
Erasca, Inc.ERAS$4.1B-33.1x12.7x-38.3%-32.0x
LivaNova PLCLIVN$4.0B-16.7x3.4x-20.2%-34.4x
Edgewise Therapeutics, Inc.EWTX$4.0B-23.9x7.7x-32.1%-20.9x
Peer median—-30.7x11.2x-27.2%-27.4x

Year-to-date ROI

TXG since 1 January, against earlier years.

Historical volatility

TXG's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

10x Genomics, Inc. operating margin by fiscal year
10x Genomics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-32.5%
FY2023-33.0%
FY2024-31.9%
FY2025-17.2%
LineFY2025
Cost of revenueCost Of Revenue$198.9M
Gross profitGross Profit$443.9M
Operating expensesOperating Expense$554.8M
Research and developmentResearch And Development$238.6M
Selling, general and administrativeSelling General And Administration$316.1M
Total expensesTotal Expenses$753.7M
Pretax incomePretax Income-$39.9M

Learn while you research

Academy chapters picked for 10x Genomics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →